Publication details

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

Authors

SVATON Martin KNETKI-WROBLEWSKA Magdalena TABOR Sylwia DOMECKY Petr VENCLÍČEK Ondřej KREJCI Jana DROSSLEROVA Marie HRNCIARIK Michal HRICISAK Daniel BEJCKOVA Alzbeta FISCHER Ondrej VITKOVA Martina KRZAKOWSKI Maciej

Year of publication 2024
Type Article in Periodical
Magazine / Source In vivo
MU Faculty or unit

Faculty of Medicine

Citation
Web https://iv.iiarjournals.org/content/38/5/2434
Doi http://dx.doi.org/10.21873/invivo.13712
Keywords Non-small cell lung cancer; pembrolizumab; overall survival; PD-L1 expression
Description Background/Aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression >= 50% showed a significant improved overall survival (OS) with increasing expression of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS in relation to the PD-L1 expression. Therefore, the objective of our study was to determine whether improvement in OS reflects increased expression levels of PD-L1 (>= 50%) >= 50%) in patients with NSCLC. Patients and Methods: Retrospective data from 9 Czech and 1 Polish comprehensive oncology Centers were used. All patients with stage IV NSCLC and PD-L1 expression >= 50% treated with pembrolizumab in daily practice were included. The groups of patients according to the expression of PD-L1 were determined as follows: PD-L1 50-59%, 60-69%, 70-79%, 80-89% and 90-100%. The log-rank test and the Cox regression model were used to compare survival between study groups. Results: A total of 617 patients were included in the study. We did not observe a statistically significant difference in OS between groups of patients with different levels of PD-L1 expression in the pooled comparison (p=0.445). Furthermore, we did not observe a statistically significant difference even when comparing OS in patients with PD-L1expression of 50-59% (reference) with the group of other patients according to the level of expression of PD- L1 in the Cox regression model including the effect covariates. Conclusion: PD-L1 expression showed no significant effect on OS in patients with NSCLC with PD- L1 >= 50% >= 50% treated with pembrolizumab.

You are running an old browser version. We recommend updating your browser to its latest version.

More info